Replicate’s srRNA rabies vaccine effective in Phase 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine.

A startup aims to compete with Vertex in pain

A new startup, Latigo Biotherapeutics, has launched with $135 million and the intention to compete with Vertex Pharmaceuticals. The company, which was incubated by the Los Angeles-area venture firm Westlake Village BioPartners, is in the midst a Phase 1 trial for a non-opioid pain medicine called LTG-001. It’s an oral drug meant to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In